ABVC BioPharma, Inc.
ABVC
$2.79
$0.05642.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 37.33% | 190.83% | 69.11% | -11.98% | -62.57% |
| Total Other Revenue | 98.29% | 98.29% | 98.29% | -986.79% | -- |
| Total Revenue | 186.88% | 1,901.57% | 234.16% | -31.04% | -82.19% |
| Cost of Revenue | -99.82% | -99.79% | -99.74% | -67.30% | -58.64% |
| Gross Profit | 1,292.07% | 334.43% | 440.17% | 18.94% | -109.21% |
| SG&A Expenses | -41.24% | -67.00% | -22.36% | -40.23% | -30.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 197.92% | 197.92% | 197.92% | -267.59% | -- |
| Total Operating Expenses | -43.29% | -69.30% | -34.75% | -54.11% | -44.42% |
| Operating Income | 48.22% | 75.79% | 40.80% | 55.93% | 41.78% |
| Income Before Tax | 59.17% | 76.73% | 49.02% | 57.01% | 30.25% |
| Income Tax Expenses | -62.15% | -143.16% | -143.16% | -93.79% | -93.95% |
| Earnings from Continuing Operations | 59.19% | 78.55% | 51.93% | 60.19% | 35.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -60.08% | -50.21% | -49.94% | 347.49% | 440.88% |
| Net Income | 59.12% | 80.20% | 52.06% | 64.57% | 40.92% |
| EBIT | 48.22% | 75.79% | 40.80% | 55.93% | 41.78% |
| EBITDA | 48.47% | 76.21% | 41.03% | 56.11% | 41.91% |
| EPS Basic | 85.30% | 92.59% | 82.38% | 87.33% | 67.48% |
| Normalized Basic EPS | 85.93% | 93.09% | 81.96% | 89.01% | 67.45% |
| EPS Diluted | 84.94% | 92.34% | 82.17% | 87.15% | 67.42% |
| Normalized Diluted EPS | 85.93% | 93.09% | 81.96% | 89.01% | 67.45% |
| Average Basic Shares Outstanding | 82.34% | 118.28% | 169.00% | 187.16% | 141.18% |
| Average Diluted Shares Outstanding | 82.34% | 118.28% | 169.00% | 187.16% | 141.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |